BioCryst_PrimaryLogo_R_2C_RGB.jpg
BioCryst Announces Peramivir NDA Acceptance by the FDA
February 25, 2014 06:45 ET | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments...
BioCryst_PrimaryLogo_R_2C_RGB.jpg
BioCryst to Present at Three Upcoming Investor Conferences
February 20, 2014 07:30 ET | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update...
BioCryst_PrimaryLogo_R_2C_RGB.jpg
BioCryst to Announce Fourth Quarter and 2013 Financial Results February 26
February 12, 2014 06:30 ET | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its fourth quarter and full year 2013 financial results will be...
BioCryst_PrimaryLogo_R_2C_RGB.jpg
BioCryst to Present at J.P. Morgan Healthcare Conference
January 02, 2014 13:03 ET | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 2, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its executives are scheduled to present a corporate summary and update...